GO:0060421 positive regulation of heart growth

GO:0060421, positive regulation of heart growth, is a Gene Ontology biological process term that encompasses any process which increases the rate or extent of heart growth, where heart growth is defined as an increase in the size or mass of the heart. This term is critical for understanding how the heart adapts to physiological and pathological stimuli, including exercise, hormonal signals, and mechanical load [1,5]. Researchers studying cardiac biology rely on this ontology term to annotate genes and pathways that promote cardiomyocyte hypertrophy, hyperplasia, or overall cardiac enlargement [5,6]. The regulation of heart growth is a complex interplay of neuroendocrine factors, growth factors, and intracellular signaling cascades [2,5,6]. For example, growth hormone-releasing peptides have been shown to exert positive inotropic and calcium-mobilizing effects on the rat heart, directly linking hormonal signaling to enhanced cardiac function and growth. Similarly, vasoactive intestinal peptide (VIP) has cardiovascular effects that include modulation of heart rate and contractility, which can influence heart growth. Catecholamines, such as epinephrine and norepinephrine, are well-established regulators of cardiac function and have been implicated in hypertension-related cardiac changes. Understanding the positive regulation of heart growth is essential for developing therapeutic strategies for heart failure, hypertrophy, and other cardiovascular diseases [2,8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0060421, covering its definition, mechanisms, key genes, disease associations, and experimental methods.

According to the Gene Ontology, GO:0060421 positive regulation of heart growth is defined as any process that increases the rate or extent of heart growth. Heart growth itself is the increase in size or mass of the heart. This term is a biological process and is used to annotate gene products that promote cardiac enlargement, whether through cardiomyocyte hypertrophy, hyperplasia, or other mechanisms. It is a positive regulatory term, meaning it specifically covers processes that upregulate or enhance heart growth, as opposed to negative regulation (GO:0060422) or the basal process of heart growth (GO:0060419).

Positive regulation of heart growth is fundamentally important because it underlies the heart's ability to adapt to increased workload, hormonal signals, and physiological demands such as exercise or pregnancy. When this process is dysregulated, it can lead to pathological cardiac hypertrophy, heart failure, and increased cardiovascular mortality. Understanding the molecular players that positively regulate heart growth provides targets for therapeutic intervention in diseases characterized by inadequate or excessive cardiac growth, including hypertension, myocardial infarction, and cardiomyopathies [2,5,6,8].

The following genes and proteins have been implicated in positive regulation of heart growth based on verified literature and their known roles in cardiac signaling, calcium handling, and transcriptional regulation.

Positive regulation of heart growth is tightly controlled by a network of signaling pathways. The calcineurin-NFAT pathway is a major regulator, activated by sustained calcium signals, leading to hypertrophic gene expression. The MAPK/ERK pathway is also involved, transducing growth factor signals from receptor tyrosine kinases. Beta-adrenergic signaling via catecholamines activates PKA and CaMKII, which can promote hypertrophy. Additionally, growth hormone-releasing peptides and VIP modulate cardiac function through G-protein coupled receptors and calcium mobilization [5,6]. Negative feedback mechanisms, including the expression of natriuretic peptides (NPPA, NPPB), act to counterbalance excessive growth.

Chronic hypertension imposes increased afterload on the heart, leading to compensatory cardiac hypertrophy through positive regulation of heart growth. Catecholamines, such as norepinephrine, are elevated in essential hypertension and contribute to cardiac remodeling and hypertrophy. This maladaptive growth can progress to heart failure if left untreated. Understanding the molecular drivers of this process is critical for developing therapies that prevent or reverse pathological hypertrophy.

Fetal growth restriction (FGR) is associated with altered heart rate variability and cardiac programming, which may affect long-term heart growth regulation. Nonlinear analyses of heart rate variability in growth-restricted fetuses indicate autonomic dysfunction, which can influence cardiac development and growth. These findings suggest that early-life events can program the heart's growth regulatory pathways, with implications for adult cardiovascular disease.

In heart failure, the heart's ability to positively regulate growth is often impaired or becomes maladaptive. Targeting the signaling pathways that drive positive regulation of heart growth, such as the GHRP and VIP pathways, may offer therapeutic benefits [5,6]. For example, GHRPs have shown positive inotropic effects, suggesting potential for improving cardiac function in heart failure patients. However, careful modulation is required to avoid excessive hypertrophy.

RNA sequencing can identify genes and pathways that are differentially expressed during positive regulation of heart growth. By comparing hypertrophic hearts to controls, researchers can uncover novel regulators and validate known players such as NPPA and NPPB.

Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status in response to growth stimuli. This is particularly useful for mapping signaling cascades involving calcium/calmodulin-dependent kinases and MAPKs.

Live-cell calcium imaging and patch-clamp electrophysiology can measure calcium transients and contractility in cardiomyocytes treated with GHRPs or VIP, providing functional evidence for their role in heart growth regulation [5,6].

Pooled CRISPR knockout or activation screens in cardiomyocyte cell lines or iPSC-derived cardiomyocytes can identify genes that positively or negatively regulate heart growth. These screens are powerful for discovering novel regulators.

Researchers studying positive regulation of heart growth-related genes often need to determine whether a candidate gene is causally involved in cardiac hypertrophy or heart failure. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with precision and efficiency.

GO:0060421 positive regulation of heart growth is a vital biological process that governs the heart's ability to increase in size and mass in response to physiological and pathological stimuli. Through hormonal, neuroendocrine, and calcium-dependent signaling pathways, this process ensures cardiac adaptation but can become maladaptive in disease. Key genes such as GHRH, VIP, ADRB1, and RYR2 have been implicated in this regulation [2,5,6]. Understanding these mechanisms is essential for developing targeted therapies for hypertension, heart failure, and other cardiovascular conditions. CRISPR-based models offer powerful tools to dissect the causal roles of individual genes, and EDITGENE stands ready to support these efforts with comprehensive gene editing and screening services.